logo-loader
viewPreveCeutical Medical Inc.

Full interview: Preveceutical announces successful preliminary evaluation of key peptides

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development program. 

Jawadeker talked about what that means for the program and the next steps for the company. 


 

Quick facts: PreveCeutical Medical Inc.

Price: 0.015 CAD

CSE:PREV
Market: CSE
Market Cap: $5.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks climb; Canntab shares soar on hemp-cultivation...

Buds of the day are Canntab Therapeutics Ltd (CSE:PILL.CN) (OTCMKTS:CTABF), PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF). The duds are The Supreme Cannabis Company Inc (TSE:FIRE) (OTCMKTS:SPRWF), BlissCo Cannabis Corp (CSE:BLIS). 

on 05/21/2019

2 min read